Kodiak Sciences Q3 net loss widens as R&D expenses rise

What happened

Kodiak Sciences reported that its third-quarter net loss widened year over year as research and development expenses increased, mainly because of more clinical and manufacturing work on studies. It ended the quarter with $88.7 in cash and raised $69 afterward through an equity offering.

Confirmed

Global impact / market context

Higher research and development spending increases costs while the company advances clinical studies, contributing to a wider loss. The later equity offering adds cash, but also means shares were issued to raise funds. Kodiak says its existing cash is expected to support operations into 2027.

Analyst inference

The supplied information presents pipeline progress alongside rising research costs: Kodiak highlighted positive Phase 3 results for Zenkuda and tabirafusp-ted, while pivotal KSI-101 studies continue. It expects to seek approval for Zenkuda by end-2026 and report initial KSI-101 Phase 3 results in December 2026.

Confirmed

What to watch

1. Watch whether Kodiak submits the Zenkuda application for three indications by the end of 2026, as planned, and whether the timeline remains on track. Proposed
2. Kodiak plans to announce first Phase 3 KSI-101 results in December 2026; those results could influence further development plans and research spending. Proposed
3. Track cash use against the company’s expectation that current cash will support operations into 2027, including the effect of ongoing clinical and manufacturing activity. Analyst inference

Evidence

• Original source link unavailable